QSAM Biosciences, Inc. (QSAM)
QSAM Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Austin, TX, US. The stock last traded at $8.30, down 99.95% on the session, giving a market capitalisation of $18,443. On trailing twelve-month figures it carries a trailing P/E of -6.69, a net margin of 0.0%. Its beta of 1.81 implies it has historically moved more than the broad market.
Based in Austin, Texas, QSAM Biosciences, Inc. is dedicated to advancing nuclear medicine for cancer and related illnesses. A key component of their pipeline is CycloSam (Samarium-153 DOTMP), a radiopharmaceutical currently in clinical development that specifically targets bone. The company holds a licensing agreement with IGL Pharma, Inc. Founded in 2004, the organization operated as Q2Earth, Inc. before rebranding to QSAM Biosciences, Inc. in September 2020.
QSAM Biosciences, Inc. is most often compared with the following Healthcare names: